17:25 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
18:58 , Sep 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting MGLL could help treat MS and other demyelinating disorders. In the experimental autoimmune encephalomyelitis (EAE) model of MS, an MGLL inhibitor tool compound decreased motor deficits compared...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Aphios, VivaCell deal

The companies partnered to develop and commercialize non-psychotropic cannabinoid drug candidates to treat multiple sclerosis and other CNS neurodegenerative diseases in the U.S. and Europe. The compounds were discovered by phytocannabinoids company VivaCell in collaboration...
07:00 , Mar 22, 2012 |  BC Innovations  |  Targets & Mechanisms

Gleevec for pain

Researchers at The University of Texas MD Anderson Cancer Center have found a potential new use for Novartis AG 's Gleevec imatinib cancer drug-reducing tolerance to opioid analgesics. 1 Gleevec prevented and reversed morphine tolerance...
07:00 , Sep 4, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Neurology Adrenomedullin (AM) A study in mice suggests that increasing AM expression may be useful for preventing neurological diseases of...
08:00 , Nov 11, 2002 |  BC Week In Review  |  Company News

Cajal Institute other research news

Researchers published in Nature Medicine that IGF-1 treatment of mice overexpressing mutant amyloid resulted in markedly reduced brain amyloid-beta burden, which is linked to the pathogenesis of Alzheimer's disease. Cajal Institute , Madrid, Spain, et...
08:00 , Feb 9, 1998 |  BC Week In Review  |  Company News

Cajal Institute other research news

Spanish researchers published the ability of IGF-1 to improve symptoms in a model of cerebellar ataxia, a movement disorder caused by degeneration in the cerebellum, the brain area involved in balance and coordination. Rats with...